Advertisement

Topics

Sunovion Submits New Drug Application for Dasotraline to the FDA for ADHD

10:11 EDT 5 Sep 2017 | Drug Discovery Development

Pharmacokinetic properties and clinical studies of dasotraline, a new chemical entity, support potential for continuous therapeutic effect over 24-hour dosing interval with once-daily dosing
Contributed Author: 
Sunovion Pharmaceuticals, Inc.
Topics: 

Original Article: Sunovion Submits New Drug Application for Dasotraline to the FDA for ADHD

NEXT ARTICLE

More From BioPortfolio on "Sunovion Submits New Drug Application for Dasotraline to the FDA for ADHD"

Quick Search
Advertisement